Archive | HAPILA GmbH
HAPILA bringing end-to-end API supply chain solutions to CPHI Barcelona
Friday 20th October 2023
Learn More >
HAPILA and ATHANA alliance receive funding for nanoparticle antifungal program
Wednesday 13th September 2023
Learn More >
HAPILA’s co-developed anti-TB agent BTZ-043 named ‘Drug of the Year’
Friday 8th September 2023
Learn More >
HAPILA shows advanced API development capabilities at Chemspec Europe 2023
Thursday 11th May 2023
Learn More >
HAPILA commences cGMP pilot scale manufacture of anti-TB API BTZ-043
Wednesday 16th November 2022
Learn More >
CEP Revision extends HAPILA Estriol API retest period to 60 months
Thursday 23rd June 2022
Learn More >
HAPILA extends co-operation with Transo-Pharm to meet Estriol demand
Tuesday 8th March 2022
Learn More >
Authorities confirm cGMP status for HAPILA’s Estriol estrogen API manufacturing
Thursday 17th February 2022
Learn More >
HAPILA starts optimized pilot scale production of BTZ-043 anti TB agent
Thursday 13th January 2022
Learn More >
HAPILA GMP focused API contract development and manufacturing
Thursday 23rd December 2021
Learn More >